Head-to-head evidence
ICP-490 vs Mezigdomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
ICP-490
Developed by Beijing InnoCare Pharma Tech Co.
NCT05719701 · Phase 1/2 · status unknown
This is an unblinded, non-randomized dose-finding study with no control arm, and no results have been posted yet, so it cannot currently demonstrate a controlled treatment effect.
Mezigdomide
Developed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT05372354 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ICP-490's landscape · Mezigdomide's landscape